CytRx Reports Completed Phase 1b/2 Progression-Free Survival and Overall Survival Aldoxorubicin Data in Second-Line Soft Tissue Sarcoma

[Business Wire] – CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, presented updated progression-free survival and overall survival results from its completed Phase 1b/2 clinical trial of aldoxorubicin in more

View todays social media effects on CYTR

View the latest stocks trending across Twitter. Click to view dashboard

See who CytRx is hiring next, click here to view